Genprex Inc. (GNPX)
GNPX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1595248/000143774925010311/0001437749-25-010311-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GNPX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001595248 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | TX |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$21.1M |
| Operating income | -$21.2M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $1.6M |
| Total assets | $4.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company's ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company's ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $15.2M cash; operating cash flow -$3.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,334,753 (2026-11-09); 2,270,346 a year earlier; 59,434,822 three years earlier. 1y figure adjusted for splits (1-for-22 overall); 3y figure adjusted for splits (1-for-44000 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | 3; latest 1-for-22 on 2026-07-16 | Source 2026-07-16 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-11-21 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-07-30 |
| Auditor | WithumSmith+Brown, PC, East Brunswick, New Jersey, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $22 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 819,709 shares at the 2026-11-13 price; the latest SEC cover count is 1,334,753 as of 2026-11-09. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$4.4M | -$5.1M | $15.2M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$4.5M | -$3.1M | $18.0M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$3.8M | -$4.1M | $7.8M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$3.8M | -$3.2M | $1.1M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$4.7M | -$3.9M | $1.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$4.0M | -$4.2M | $3.5M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$4.3M | -$3.9M | $1.6M | No debt tags | $0 | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$4.3M | -$2.2M | $1.5M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-06-05 |
| Latest annual report FORM 10-K | 10-K | 2026-03-30 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-13 |
| Latest current report FORM 8-K | 8-K | 2026-11-05 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 492 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | -17.1% |
| 3 months | -57.3% |
| Year to date | -94.6% |
| 1 year | -97.7% |
| From 52-week high | -97.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| REVB | Revelation Biosciences Inc. | $3.82 | -10.43% | $2.6M |
| EOCN | Eocene Ltd. | $2.53 | +5.86% | $2.6M |
| PRFX | PRF Technologies Ltd. | $0.6948 | -11.22% | $2.4M |
| PPBT | Purple Biotech Ltd. | $1.68 | +3.70% | $2.7M |
| ERNA | Ernexa Therapeutics Inc. | $1.69 | +0.60% | $2.9M |
| JUNS | Jupiter Neurosciences Inc. | $1.70 | -8.11% | $2.2M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier